Annual CFF
$12.64 M
+$12.72 M+16142.26%
December 31, 2023
Summary
- As of February 12, 2025, GANX annual cash flow from financing activities is $12.64 million, with the most recent change of +$12.72 million (+16142.26%) on December 31, 2023.
- During the last 3 years, GANX annual CFF has risen by +$2.15 million (+20.54%).
- GANX annual CFF is now -69.73% below its all-time high of $41.77 million, reached on December 31, 2021.
Performance
GANX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$808.70 K
-$9.23 M-91.94%
September 30, 2024
Summary
- As of February 12, 2025, GANX quarterly cash flow from financing activities is $808.70 thousand, with the most recent change of -$9.23 million (-91.94%) on September 30, 2024.
- Over the past year, GANX quarterly CFF has dropped by -$8.75 million (-91.54%).
- GANX quarterly CFF is now -98.07% below its all-time high of $41.99 million, reached on March 31, 2021.
Performance
GANX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$20.26 M
+$674.20 K+3.44%
September 30, 2024
Summary
- As of February 12, 2025, GANX TTM cash flow from financing activities is $20.26 million, with the most recent change of +$674.20 thousand (+3.44%) on September 30, 2024.
- Over the past year, GANX TTM CFF has increased by +$7.62 million (+60.27%).
- GANX TTM CFF is now -60.34% below its all-time high of $51.08 million, reached on March 31, 2021.
Performance
GANX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
GANX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10000.0% | -91.5% | +60.3% |
| 3 y3 years | +20.5% | +8437.1% | -51.5% |
| 5 y5 years | +1185.0% | +8437.1% | -51.5% |
GANX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -69.7% | >+9999.0% | -91.9% | +654.7% | -51.5% | +7847.6% |
| 5 y | 5-year | -69.7% | >+9999.0% | -98.1% | +283.7% | -60.3% | +7847.6% |
| alltime | all time | -69.7% | >+9999.0% | -98.1% | +283.7% | -60.3% | +7847.6% |
Gain Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $808.70 K(-91.9%) | $20.26 M(+3.4%) |
| Jun 2024 | - | $10.04 M(-6983.7%) | $19.59 M(+66.7%) |
| Mar 2024 | - | -$145.80 K(-101.5%) | $11.75 M(-7.1%) |
| Dec 2023 | $12.64 M(<-9900.0%) | $9.56 M(+7008.3%) | $12.64 M(+313.2%) |
| Sep 2023 | - | $134.50 K(-93.9%) | $3.06 M(+5.3%) |
| Jun 2023 | - | $2.20 M(+193.4%) | $2.90 M(+310.1%) |
| Mar 2023 | - | $748.90 K(-3567.1%) | $708.10 K(-998.6%) |
| Dec 2022 | -$78.80 K(-100.2%) | -$21.60 K(+4.9%) | -$78.80 K(+17.8%) |
| Sep 2022 | - | -$20.60 K(-1571.4%) | -$66.90 K(+44.5%) |
| Jun 2022 | - | $1400.00(-103.7%) | -$46.30 K(-82.3%) |
| Mar 2022 | - | -$38.00 K | -$261.50 K |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | $41.77 M(+298.3%) | - | - |
| Dec 2021 | - | -$9700.00(<-9900.0%) | $41.77 M(+1.0%) |
| Sep 2021 | - | $0.00(-100.0%) | $41.34 M(-18.8%) |
| Jun 2021 | - | -$213.80 K(-100.5%) | $50.88 M(-0.4%) |
| Mar 2021 | - | $41.99 M(-9636.7%) | $51.08 M(+387.1%) |
| Dec 2020 | $10.49 M(+498.7%) | - | - |
| Dec 2020 | - | -$440.30 K(-104.6%) | $10.49 M(-4.0%) |
| Sep 2020 | - | $9.55 M(<-9900.0%) | $10.93 M(+690.6%) |
| Jun 2020 | - | -$10.60 K(-100.8%) | $1.38 M(-0.8%) |
| Mar 2020 | - | $1.39 M | $1.39 M |
| Dec 2019 | $1.75 M(+78.0%) | - | - |
| Dec 2018 | $983.80 K | - | - |
FAQ
- What is Gain Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Gain Therapeutics?
- What is Gain Therapeutics annual CFF year-on-year change?
- What is Gain Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Gain Therapeutics?
- What is Gain Therapeutics quarterly CFF year-on-year change?
- What is Gain Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Gain Therapeutics?
- What is Gain Therapeutics TTM CFF year-on-year change?
What is Gain Therapeutics annual cash flow from financing activities?
The current annual CFF of GANX is $12.64 M
What is the all time high annual CFF for Gain Therapeutics?
Gain Therapeutics all-time high annual cash flow from financing activities is $41.77 M
What is Gain Therapeutics annual CFF year-on-year change?
Over the past year, GANX annual cash flow from financing activities has changed by +$12.72 M (+16142.26%)
What is Gain Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of GANX is $808.70 K
What is the all time high quarterly CFF for Gain Therapeutics?
Gain Therapeutics all-time high quarterly cash flow from financing activities is $41.99 M
What is Gain Therapeutics quarterly CFF year-on-year change?
Over the past year, GANX quarterly cash flow from financing activities has changed by -$8.75 M (-91.54%)
What is Gain Therapeutics TTM cash flow from financing activities?
The current TTM CFF of GANX is $20.26 M
What is the all time high TTM CFF for Gain Therapeutics?
Gain Therapeutics all-time high TTM cash flow from financing activities is $51.08 M
What is Gain Therapeutics TTM CFF year-on-year change?
Over the past year, GANX TTM cash flow from financing activities has changed by +$7.62 M (+60.27%)